Short Interest in Anixa Biosciences, Inc. (NASDAQ:ANIX) Expands By 13.7%

Anixa Biosciences, Inc. (NASDAQ:ANIX) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 403,100 shares, an increase of 13.7% from the January 15th total of 354,500 shares. Based on an average daily volume of 121,000 shares, the days-to-cover ratio is presently 3.3 days. Approximately 1.3% of the company’s shares are sold short.

Anixa Biosciences Trading Down 0.3 %

NASDAQ ANIX opened at $3.14 on Friday. The company has a fifty day simple moving average of $2.70 and a 200 day simple moving average of $3.05. Anixa Biosciences has a 12-month low of $2.07 and a 12-month high of $4.35. The company has a market cap of $101.11 million, a P/E ratio of -8.05 and a beta of 0.93.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. Sell-side analysts predict that Anixa Biosciences will post -0.46 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Amit Kumar acquired 43,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was bought at an average price of $2.23 per share, for a total transaction of $95,890.00. Following the purchase, the chief executive officer now directly owns 559,925 shares of the company’s stock, valued at $1,248,632.75. The trade was a 8.32 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Lewis H. Titterton, Jr. acquired 10,000 shares of the stock in a transaction dated Friday, January 17th. The stock was bought at an average price of $2.57 per share, with a total value of $25,700.00. Following the purchase, the director now directly owns 922,334 shares in the company, valued at $2,370,398.38. This represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders bought 75,289 shares of company stock worth $177,021. 22.60% of the stock is currently owned by insiders.

Institutional Trading of Anixa Biosciences

Hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC boosted its holdings in Anixa Biosciences by 36.5% during the 4th quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock worth $34,000 after acquiring an additional 3,900 shares during the last quarter. Virtu Financial LLC purchased a new position in Anixa Biosciences during the 3rd quarter worth $34,000. LPL Financial LLC boosted its holdings in Anixa Biosciences by 37.2% during the 4th quarter. LPL Financial LLC now owns 42,937 shares of the company’s stock worth $100,000 after acquiring an additional 11,633 shares during the last quarter. Tyler Stone Wealth Management boosted its holdings in Anixa Biosciences by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after acquiring an additional 21,008 shares during the last quarter. Finally, Westside Investment Management Inc. boosted its holdings in Anixa Biosciences by 151.8% during the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after acquiring an additional 21,100 shares during the last quarter. Institutional investors and hedge funds own 29.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ANIX. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Wednesday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, November 19th.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.